Lymphoma

Breyanzi was approved by the U.S. FDA on February 5, 2021, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy developed by the American pharmaceutical company Bristol Myers Squibb (BMS) for the first-line treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after treatment.

In the ever-evolving landscape of cancer treatment, CAR-T (Chimeric Antigen Receptor T-cell) therapy has emerged as a game-changer, offering hope to patients with relapsed or refractory hematological malignancies.

Breyanzi (lisocabtagene maraleucel), a CD19-directed chimeric antigen receptor T cell (CAR-T) therapy, developed by Bristol Myers Squibb (BMS), has made significant strides in the field of cancer treatment since its initial FDA approval in 2021.

In the rapidly evolving field of cancer immunotherapy, CAR-T (Chimeric Antigen Receptor T-Cell) therapy has emerged as a groundbreaking treatment modality.

Cancer remains one of the most challenging diseases to treat, with millions of people affected worldwide.

On July 24, 2020, the U.S. FDA announced accelerated approval of the CAR-T cell therapy Brexucabtagene Autoleucel (Tecartus) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

On May 30, 2024, Bristol Myers Squibb (BMS) announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel, liso-cel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

On August 24, 2021, Novartis announced that in the BELINDA Phase III clinical trial, the use of Kymriah (CTL019, tisagenlecleucel) as a second-line treatment for patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) failed to meet the primary endpoint of event-free survival (EFS) compared to standard of care (SOC).

Axicabtagene ciloleucel (trade name: Yescarta) is a chimeric antigen receptor (CAR) T-cell therapy used to treat certain types of non-Hodgkin’s lymphoma.

The treatment carries a staggering price tag of around $373,000 per patient in the United States.